Expertise in
12
conditions

Dr. Ragini Kudchadkar

Oncology
Emory University School Of Medicine Department Of Ophthalmology
1365 Clifton Rd NE, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
12
conditions
Emory University School Of Medicine Department Of Ophthalmology
1365 Clifton Rd NE, 
Atlanta, GA 

Overview

Ragini Kudchadkar is an Oncologist practicing medicine in Atlanta, Georgia.

Dr. Kudchadkar is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Basal Cell Skin Cancer, and Melanoma of the Eye.

She is actively involved in clinical research, co-authoring 97 peer reviewed articles and participating in 13 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Emory University School of Medicine Department of Ophthalmology
1365 Clifton Rd NE, Atlanta, GA 30322

Additional Areas of Focus

Dr. Kudchadkar has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Pilot Study of Neoadjuvant/Adjuvant Cemiplimab for High Risk Cutaneous Squamous Cell Carcinoma
Pilot Study of Neoadjuvant/Adjuvant Cemiplimab for High Risk Cutaneous Squamous Cell Carcinoma
Enrollment Status: Recruiting
Publish Date: August 14, 2025
Intervention Type: Radiation, Biological, Procedure
Study Drug: Cemiplimab
Study Phase: Phase 1
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Drug, Other
Study Phase: Phase 2
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Biological
Study Phase: Phase 1
A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma
A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: June 26, 2024
Intervention Type: Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

97 Total Publications

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
Journal: Future oncology (London, England)
Published: October 15, 2025
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required
Before you request

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.3 miles away)
404-778-1900
Languages Spoken:
English, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Suresh Ramalingam is an Oncologist practicing medicine in Atlanta, Georgia. Dr. Ramalingam is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Ramalingam is board certified in American Board Of Internal Medicine, 2003. Dr. Ramalingam is currently accepting new patients.

Expertise in
5
conditions
Dr. Carlton D. Dampier
Hematology | Oncology
Expertise in
5
conditions
Dr. Carlton D. Dampier
Hematology | Oncology
Referral may be required

Children's Healthcare Of Atlanta At Hughes Spalding

35 Jesse Hill Jr Dr SE, 
Atlanta, GA 
 (4.4 miles away)
404-785-9800
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Carlton Dampier is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Dampier is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Dampier is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required
Before you request

Winship Cancer Institute Of Emory University

1365 Clifton Rd Ne, Bldg C, 
Atlanta, GA 
 (0.1 miles away)
Experience:
18+ years
Languages Spoken:
English, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mehmet Bilen is an Oncologist practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 18 years. Dr. Bilen is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Tissue Biopsy. Dr. Bilen is board certified in American Board Of Internal Medicine, 2016. Dr. Bilen is currently accepting new patients.

Frequently Asked Questions about Dr. Ragini Kudchadkar

How do I make an appointment with Dr. Ragini Kudchadkar?

You can book an appointment with Dr. Ragini Kudchadkar by calling their office at 404-778-1900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ragini Kudchadkar a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ragini Kudchadkar is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ragini Kudchadkar specialize in?

While Dr. Ragini Kudchadkar is a Oncology, they have specific expertise in Melanoma, Merkel Cell Carcinoma, and Basal Cell Skin Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Ragini Kudchadkar participate in research or clinical trials?

Yes. Dr. Ragini Kudchadkar has published 97 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Ragini Kudchadkar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ragini Kudchadkar accept my insurance?

Dr. Ragini Kudchadkar accepts most major insurance plans, including Cigna and Humana. We recommend calling the office directly at 404-778-1900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kudchadkar's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 50 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile